Skip to Content
MilliporeSigma

Inhibitor eradication with rituximab in haemophilia: where do we stand?

British journal of haematology (2014-03-19)
Massimo Franchini, Pier Mannuccio Mannucci
ABSTRACT

Rituximab is a humanized chimeric anti-CD20 monoclonal antibody initially developed for the treatment of some haematological malignancies. Thanks to its ability to rapidly and specifically deplete B cells, it has also been used in a variety of autoimmune disorders, haematological or not. In this context, during the last decade several small case series have documented successful inhibitor eradication with rituximab, alone or in combination with other immunosuppressive agents, in patients with acquired haemophilia A refractory to standard therapy. In addition, a number of investigators have recently used this agent in patients with congenital haemophilia A or B and alloantibodies refractory to first-line treatment. This article critically reviews the current knowledge on the use of rituximab in acquired haemophilia or congenital haemophilia complicated by alloantibodies, also providing treatment algorithms for the management of these conditions.

MATERIALS
Product Number
Brand
Product Description

Human coagulation factor VIII concentrate, European Pharmacopoeia (EP) Reference Standard
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
5 g
In Stock
Details...
₩57,246
250 g
Estimated to ship on April 14, 2025
Details...
₩116,725
1 kg
Estimated to ship on April 14, 2025
Details...
₩283,490
Sigma-Aldrich
Factor IX human, aqueous glycerol solution, ≥145 units/mg protein
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
5 g
In Stock
Details...
₩57,246
250 g
Estimated to ship on April 14, 2025
Details...
₩116,725
1 kg
Estimated to ship on April 14, 2025
Details...
₩283,490